Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2010-08-05

Original market date: See footnote 1

2000-05-05

Product name:

METADOL

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02241377

Product Monograph/Veterinary Labelling:

Date: 2021-02-25 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

PALADIN PHARMA INC.
100 Blvd Alexis-Nihon, Suite 600
Montreal
Quebec
Canada H4M 2P2

Class:

Human

Dosage form(s):

Solution

Route(s) of administration:

Oral

Number of active ingredient(s):

1

Schedule(s):

Narcotic (CDSA I)

 

American Hospital Formulary Service (AHFS): See footnote 3

28:08.08 

Anatomical Therapeutic Chemical (ATC): See footnote 4

N07BC02 METHADONE

Active ingredient group (AIG) number:See footnote5

0144621001

List of active ingredient(s)
Active ingredient(s) See footnote8 Strength
METHADONE HYDROCHLORIDE 10 MG / ML

Risk Management Plans See footnote 7

A Canadian Specific Opioid targeted Risk Management Plan (CSO-tRMP) for this product was submitted.

Additional Risk Minimization Measures
Healthcare Professional Education
Version 4.0.3

"Page details"

Date modified: